2
PharmaSages_June FDA Approvals CUBIST PHARMS : SIVEXTRO (tedizolid phosphate) is an oxazolidinone-class antibacterial drug indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. DOW PHARM : JUBLIA (efinaconazole) is an azole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum and Trichophyton mentagrophytes. New dosage form of REYATAZ (atazanavir) from BRISTOL MYERS SQUIBB and BUNAVAIL (buprenorphine and naloxone) from BIODELIVERY SCIENCES INC were approved. New formulation or new manufacturer of VOGELXO™ (testosterone) from UPSHER SMITH LABS, AFREZZA® (insulin human) from MANNKIND CORP, and VAZCULEP (phenylephrine hydrochloride) from ECLAT PHARMS LLC were approved.

Pharmasages june fda approvals

Embed Size (px)

DESCRIPTION

CUBIST PHARMS: SIVEXTRO (tedizolid phosphate) is an oxazolidinone-class antibacterial drug indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. DOW PHARM: JUBLIA (efinaconazole) is an azole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum and Trichophyton mentagrophytes. New dosage form of REYATAZ (atazanavir) from BRISTOL MYERS SQUIBB and BUNAVAIL (buprenorphine and naloxone) from BIODELIVERY SCIENCES INC were approved. New formulation or new manufacturer of VOGELXO™ (testosterone) from UPSHER SMITH LABS, AFREZZA® (insulin human) from MANNKIND CORP, and VAZCULEP (phenylephrine hydrochloride) from ECLAT PHARMS LLC were approved.

Citation preview

Page 1: Pharmasages june fda approvals

PharmaSages_June FDA ApprovalsCUBIST PHARMS: SIVEXTRO (tedizolid phosphate) is an oxazolidinone-class antibacterial drug indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.

DOW PHARM: JUBLIA (efinaconazole) is an azole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum and Trichophyton mentagrophytes.

New dosage form of REYATAZ (atazanavir) from BRISTOL MYERS SQUIBB and BUNAVAIL (buprenorphine and naloxone) from BIODELIVERY SCIENCES INC were approved.

New formulation or new manufacturer of VOGELXO™ (testosterone) from UPSHER SMITH LABS, AFREZZA® (insulin human) from MANNKIND CORP, and VAZCULEP (phenylephrine hydrochloride) from ECLAT PHARMS LLC were approved.

Page 2: Pharmasages june fda approvals

Contact us

Ajay Shrivastava, CEO

PharmaSages58 Magnolia Lane

Princeton, NJ 08540Phone: (609)423-7602

E-mail:[email protected]: www.pharmasages.com

tel:(609)423-7602
mailto:[email protected]
http://www.pharmasages.com/

2014 - Annual report€¦ · pets. Analysis of FDA Center for Veterinary Medicine (“CVM”) approvals reveals that 91% of FDA-approved drugs for pets have no generic equivalent

2014 - Annual report€¦ · pets. Analysis of FDA Center for Veterinary Medicine (“CVM”) approvals reveals that 91% of FDA-approved drugs for pets have no generic equivalent

Documents
POLICY ON CONTRACT REVIEW, SIGNING AND REQUIRED APPROVALS ... · POLICY ON CONTRACT REVIEW, SIGNING AND REQUIRED APPROVALS Effective Date: June 7, 2013 Originating Office: Board of

POLICY ON CONTRACT REVIEW, SIGNING AND REQUIRED APPROVALS ... · POLICY ON CONTRACT REVIEW, SIGNING AND REQUIRED APPROVALS Effective Date: June 7, 2013 Originating Office: Board of

Documents
PAH-Specific Therapies: US FDA Approvals

PAH-Specific Therapies: US FDA Approvals

Documents
Keeping Up with FDA Drug approvals: 60 New drugs in 60 minutes · Privileged and Confidential April 10, 2019 Keeping Up with FDA Drug Approvals: 60 New Drugs in 60 Minutes Elizabeth

Keeping Up with FDA Drug approvals: 60 New drugs in 60 minutes · Privileged and Confidential April 10, 2019 Keeping Up with FDA Drug Approvals: 60 New Drugs in 60 Minutes Elizabeth

Documents
Education and Training Committee – 8 June 2010 Approvals

Education and Training Committee – 8 June 2010 Approvals

Documents
Regulatory Background and Past FDA Approvals in Colorectal Cancer Amna Ibrahim M.D DODP, FDA

Regulatory Background and Past FDA Approvals in Colorectal Cancer Amna Ibrahim M.D DODP, FDA

Documents
RheTech, Inc. Material Approvals by Product...RheTech Part # Description Color OEM: FDA, NSF, UL Specification: UL 94 HB CC40UP250-01 40% CC PP COPO BK UL 94HB BLACK OEM: FDA, NSF,

RheTech, Inc. Material Approvals by Product...RheTech Part # Description Color OEM: FDA, NSF, UL Specification: UL 94 HB CC40UP250-01 40% CC PP COPO BK UL 94HB BLACK OEM: FDA, NSF,

Documents
Challenges in Getting Global Approvals for Post-approval Changespqri.org/wp-content/uploads/2015/11/Chang2.pdf ·  · 2015-11-19Global Approvals for Post-approval Changes FDA/PQRI

Challenges in Getting Global Approvals for Post-approval Changespqri.org/wp-content/uploads/2015/11/Chang2.pdf ·  · 2015-11-19Global Approvals for Post-approval Changes FDA/PQRI

Documents
GE Healthcare Driving Innovation...MR guided focused ultrasound by InSightec, Ltd. Regulatory Procedure Approvals •2006 – FDA Uterine fibroids •2012 – FDA Bone metastasis •2013

GE Healthcare Driving Innovation...MR guided focused ultrasound by InSightec, Ltd. Regulatory Procedure Approvals •2006 – FDA Uterine fibroids •2012 – FDA Bone metastasis •2013

Documents
DRUG PRICING APPROVALS US FDA, But Gene Therapy ......Pharma intelligence informa PinkSheet pink.pharmaintelligence.informa.com Vol. 81 / No. 3 January 21, 2019 US FDA Shutdown Bite

DRUG PRICING APPROVALS US FDA, But Gene Therapy ......Pharma intelligence informa PinkSheet pink.pharmaintelligence.informa.com Vol. 81 / No. 3 January 21, 2019 US FDA Shutdown Bite

Documents
Tissue Adverse Event Reporting at FDA Reporting FDA Wang, June... · Tissue Adverse Event Reporting at FDA June 6, 2006 Tissue Transplant Safety Network Su Wang, MD MPH Epidemic Intelligence

Tissue Adverse Event Reporting at FDA Reporting FDA Wang, June... · Tissue Adverse Event Reporting at FDA June 6, 2006 Tissue Transplant Safety Network Su Wang, MD MPH Epidemic Intelligence

Documents
2017 New Drug Therapy Approvals - Food and Drug ... fda/published/2017-New...2017 New Drug Therapy Approvals 5 Introduction Welcome to our new report, Advancing Health through Innovation:

2017 New Drug Therapy Approvals - Food and Drug ... fda/published/2017-New...2017 New Drug Therapy Approvals 5 Introduction Welcome to our new report, Advancing Health through Innovation:

Documents
Rare Disease Drug Development: An FDA Perspective...Orphan’DrugDesignations/Approvals 0 25 50 75 100 125 150 175 200 225 250 No of Designated and Approvals 83 84 85 86 87 88 89 90

Rare Disease Drug Development: An FDA Perspective...Orphan’DrugDesignations/Approvals 0 25 50 75 100 125 150 175 200 225 250 No of Designated and Approvals 83 84 85 86 87 88 89 90

Documents
FDA Drug and-biologic-approvals-2016

FDA Drug and-biologic-approvals-2016

Health & Medicine
QbD FDA Examples for HU June 2012

QbD FDA Examples for HU June 2012

Documents
IPEC Americas & IQ Consortium - FDA meeting to discuss ... Americas & IQ Consortium - FDA meeting to discuss Novel Excipients Initiative June 4, 2015 Attendees FDA STAFF ORGANIZATION:

IPEC Americas & IQ Consortium - FDA meeting to discuss ... Americas & IQ Consortium - FDA meeting to discuss Novel Excipients Initiative June 4, 2015 Attendees FDA STAFF ORGANIZATION:

Documents
Re: Docket No. FDA 2013 N 1073: Complex Issues in ... · product approvals, appropriate reimbursement, and access to international markets. AdvaMed commends FDA for holding the January

Re: Docket No. FDA 2013 N 1073: Complex Issues in ... · product approvals, appropriate reimbursement, and access to international markets. AdvaMed commends FDA for holding the January

Documents
DARPA Revolutionizing Prosthetics 2009 - dtic.mil · DARPA Revolutionizing Prosthetics 2009 Program ... FDA approvals, and manufacturing transition. Mission Apply an understanding

DARPA Revolutionizing Prosthetics 2009 - dtic.mil · DARPA Revolutionizing Prosthetics 2009 Program ... FDA approvals, and manufacturing transition. Mission Apply an understanding

Documents
FDA Briefing Document Pharmacy Compounding …...FDA Briefing Document Page 4 June 23, 2016 FDA is considering those substances nominated for inclusion on the list of bulk drug substances

FDA Briefing Document Pharmacy Compounding …...FDA Briefing Document Page 4 June 23, 2016 FDA is considering those substances nominated for inclusion on the list of bulk drug substances

Documents
CHAPTER 7 – FDA DRUG APPROVALS, 2000-2010 Introduction€¦ · CHAPTER 7 – FDA DRUG APPROVALS, 2000-2010 Introduction This chapter reviews drug delivery enabled/enhanced product

CHAPTER 7 – FDA DRUG APPROVALS, 2000-2010 Introduction€¦ · CHAPTER 7 – FDA DRUG APPROVALS, 2000-2010 Introduction This chapter reviews drug delivery enabled/enhanced product

Documents
FDA Approvals, IND, IDE and Clinical Trials

FDA Approvals, IND, IDE and Clinical Trials

Documents
ISPE-FDA 3 Annual CGMP Conference 2 – 4 June 2014 ... · ISPE-FDA 3rd Annual CGMP Conference 2 – 4 June 2014 Baltimore, MD 5 13 FDA Regulations (expectation) • 21 CFR 211.68

ISPE-FDA 3 Annual CGMP Conference 2 – 4 June 2014 ... · ISPE-FDA 3rd Annual CGMP Conference 2 – 4 June 2014 Baltimore, MD 5 13 FDA Regulations (expectation) • 21 CFR 211.68

Documents
2014 FDA Drug Approvals

2014 FDA Drug Approvals

Technology
University of Minnesota UPlan Formulary July 2014 · Generic drug approvals by the U.S. Food and Drug Administration (FDA) since 1984, and most generic approvals 2014 University of

University of Minnesota UPlan Formulary July 2014 · Generic drug approvals by the U.S. Food and Drug Administration (FDA) since 1984, and most generic approvals 2014 University of

Documents
MEDICAL DEVICE CYBERSECURITY: FDA APPROACHphoenixmed.arizona.edu/sites/default/files/events/images/schwartz-cybermed.pdfmedical device cybersecurity: fda approach cybermed summit june

MEDICAL DEVICE CYBERSECURITY: FDA APPROACHphoenixmed.arizona.edu/sites/default/files/events/images/schwartz-cybermed.pdfmedical device cybersecurity: fda approach cybermed summit june

Documents
Discovery of A2AR Antagonist HTL1071/AZD4635 using SBDD A2a Discover… · Christopher et al. Med. Chem. Rev. 2018, 69. FDA Drug Approvals FIC vs BIC GPCR Approvals • 116 GPCR targeted

Discovery of A2AR Antagonist HTL1071/AZD4635 using SBDD A2a Discover… · Christopher et al. Med. Chem. Rev. 2018, 69. FDA Drug Approvals FIC vs BIC GPCR Approvals • 116 GPCR targeted

Documents
GAO-18-140, FDA MEDICAL DEVICE REVIEWS: …Services agreed with GAO’s recommendation. Page i GAO-18-140 Least Burdensome Medical Device Approvals Letter 1 Background 5 FDA Frequently

GAO-18-140, FDA MEDICAL DEVICE REVIEWS: …Services agreed with GAO’s recommendation. Page i GAO-18-140 Least Burdensome Medical Device Approvals Letter 1 Background 5 FDA Frequently

Documents
Payers’Guide toNew FDA Approvals

Payers’Guide toNew FDA Approvals

Documents
FDA Perspectives on Human Factors in Device Development (June

FDA Perspectives on Human Factors in Device Development (June

Documents
Rare Cancer Trial Design: Lessons from FDA Approvals · Published OnlineFirst June 20, 2012; DOI: 10.1158/1078-0432.CCR-12-1135 . The challenges of conducting clinical trials to investigate

Rare Cancer Trial Design: Lessons from FDA Approvals · Published OnlineFirst June 20, 2012; DOI: 10.1158/1078-0432.CCR-12-1135 . The challenges of conducting clinical trials to investigate

Documents